Correlation of K-ras Gene Mutations with the Protein Expressions of TAK1 and MAP4K2 in Colorectal Cancer
Abstract
To analyze the correlation of K-ras gene mutations with the protein expressions of transforming growth factor-β activating kinase 1 (TAK1) protein and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) protein in colorectal cancer. Methods K-ras gene mutations were detected by DNA sequencing analysis, and the expressions of TAK1 protein and MAP4K2 protein were detected by immunohistochemical method in 76 cases of colorectal cancer tissues. Results In 76 cases of colorectal cancer tissues, the mutation rate of K-ras gene was 32.89% (25 cases), and K-ras gene mutations were correlated with the degrees of cell differentiation ( P<0.05). The positive rates of TAK1 protein and MAP4K2 protein were 48.68% and 46.05%, respectively. The protein expressions of TAK1 and MAP4K2 were positively correlated with the degrees of cell differentiation and lymph node metastases, respectively ( P<0.05). There was no correlation between K-ras gene mutation and either TAK1 protein or MAP4K2 protein expression ( P>0.05). In 25 cases of colorectal cancer with K-ras mutation, the expression of TAK1 protein was positively correlated with the expression of MAP4K2 protein ( P<0.05). Conclusion K-ras gene mutation, TAK1 and MAP4K2 protein expressions were related to the degree of differentiation of colorectal cancer, but not to the depth of invasion. In colorectal cancer with K-ras gene mutation, the expression of TAK1 protein was positively correlated with the expression of MAP4K2 protein.
Keywords: Colorectal cancer, K-ras, TAK1, MAP4K2
Full Text:
PDFReferences
DE ROOCK W, DE VRIENDT V. NORMANNO N. et al. KRAS, В RAF, PIK3CA, and PTEN mutations; implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol,2011,12(6);594-603.
HERREROS-VILLANUEVA M, CHEN CC, YUAN SS, et al. KRAS mutations; analytical considerations. Clin Chim Acta,2014,431: 211-220[2018-01-10]. https://doi. org/10. 1016/j. cca. 2014.01.049.
SINGH A, SWEENEY MF, YU M, et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell, 2012,148(4);639-650.
MCNEW KL, WHIPPLE WJ, MEHTA AK, et al. MEK and TAK1 regulate apoptosis in colon cancer cells with KRAS-dependent activation of proinflammatory signaling. Mol Cancer Res,2016,14( 12) s 1204-1216.
CHEN YR, TAN TH. Thec-Jun N-terminal kinase pathway and apoptotic signaling (review). Int J Oncol,2000,16(4) : 651-662.
KYRIAKIS JM, AVRUCH J. Mammalian МАРК signal transduction pathways activated by stress and inflammation:a 10-year update. Physiol Rev,2012,92(2) ;689-737.
LIAO WT, WANG X, XU LH, et al. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Cancer,2009, 115(7):1507-1517.
JAUHRI M, BHATNAGAR A, GUPTA S, et al. Prevalence and coexistence of KRAS, BRAF, PIKZCA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: next-generation sequencing-based cohort study. Tumour Biol,2017,39(2): 1010428317692265.
LI ZZ. BAI L, WANG F. et al. Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. Med Oncol,2016,33(7) ; 71.
YUNXIA Z, JUN C, GUANSHAN Z, et al. Mutations in epidermal growth factor receptor and К rcis in Chinese patients with colorectal cancer. BMC Med Genet, 2010, 11; 34.
JIANG Y, KIMCHI ET, ST A VELEY-O’CARROLL KF, et al. Assessment of K-ras mutation;a step toward personalized medicine for patients with colorectal cancer. Cancer. 2009. 115(16):3609-3617.
CHANG YS, YEH KT, CHANG TJ, et al. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer,2009,9; 179.
DAHABREH IJ, TERASAWA T. CASTALDI PJ, et al. Systematic review; anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med,2011 ,154(1);37-49.
IVANOV VN, KEHRL JH, RONAI Z. Role of TRAF2/ GCK in melanoma sensitivity to UV-induced apoptosis. Oncogene,2000,19(7):93 3-9 4 2.
I)U J, WANG Y. CHEN D, et al. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-kappaB. Cancer Lett,2016,383(2);145-153.
Refbacks
- There are currently no refbacks.
